Cargando…
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
Recurrent, metastatic disease represents the most frequent cause of death for patients with thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients. Unfortunately, many thyroid cancer patients have tumors that no longer trap iodine, and hence are refractory to R...
Autores principales: | Aashiq, Mohamed, Silverman, Deborah A., Na’ara, Shorook, Takahashi, Hideaki, Amit, Moran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770909/ https://www.ncbi.nlm.nih.gov/pubmed/31533238 http://dx.doi.org/10.3390/cancers11091382 |
Ejemplares similares
-
Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017) -
New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review
por: Wong, Kai-Pun, et al.
Publicado: (2012) -
Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma
por: Na’ara, Shorook, et al.
Publicado: (2016) -
Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer
por: Choi, Yoon Ju, et al.
Publicado: (2021) -
Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)